British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

The film and photos are part of a national public health initiative, THRIVE@50+, that GSK is running to educate people 50 and older about their risk for shingles. GSK is encouraging people to ask ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares opened today at p1,644. ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...